Blurbs

Analysts Offer Insights on Healthcare Companies: Eiger Biopharmaceuticals (EIGR), Sanofi (OtherSNYNF) and Processa Pharmaceuticals (PCSA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eiger Biopharmaceuticals (EIGRResearch Report), Sanofi (SNYNFResearch Report) and Processa Pharmaceuticals (PCSAResearch Report).

Eiger Biopharmaceuticals (EIGR)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Eiger Biopharmaceuticals, with a price target of $28.00. The company’s shares closed last Thursday at $4.65.

According to TipRanks.com, Higgins is a 4-star analyst with an average return of 4.2% and a 29.9% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Armata Pharmaceuticals, and Rhythm Pharmaceuticals.

Currently, the analyst consensus on Eiger Biopharmaceuticals is a Strong Buy with an average price target of $35.00, implying a 627.7% upside from current levels. In a report issued on October 27, Robert W. Baird also maintained a Buy rating on the stock with a $29.00 price target.

See today’s best-performing stocks on TipRanks >>

Sanofi (SNYNF)

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Sanofi today and set a price target of EUR85.00. The company’s shares closed last Thursday at $86.75.

According to TipRanks.com, Papadakis is a 4-star analyst with an average return of 3.4% and a 56.8% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Sanofi-Aventis Sa, Roche Holding AG, and Morphosys Ag.

Sanofi has an analyst consensus of Moderate Buy, with a price target consensus of $100.94, a 16.7% upside from current levels. In a report issued on October 28, Kepler Capital also downgraded the stock to Hold with a EUR89.00 price target.

Processa Pharmaceuticals (PCSA)

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Processa Pharmaceuticals, with a price target of $9.00. The company’s shares closed last Thursday at $2.16, close to its 52-week low of $1.50.

According to TipRanks.com, Rahman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -38.1% and a 16.2% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Neurosense Therapeutics Ltd., and Vertex Pharmaceuticals.

Currently, the analyst consensus on Processa Pharmaceuticals is a Moderate Buy with an average price target of $8.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on EIGR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More